Drug Trial Radar · NCT03298867
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Oct 4, 2017
Primary completion
Feb 13, 2019
Study completion Nov 30, 2020
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Oct 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody \[mAb\] inhibitor of the insulin-like growth factor-1 receptor \[IGF-1R\]) administered once every 3 weeks (q3W) for 21 weeks with a final assessment at Week 24, in comparison to placebo, in the treatment of participants with moderate-to-severe active thyroid eye disease (TED).
Conditions
- Thyroid Eye Disease
- Graves' Orbitopathy
Interventions
TeprotumumabBiological
Teprotumumab is a fully human anti-IGF-1R mAb. Teprotumumab will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of teprotumumab must be reconstituted with 10 mL of water for injection. Reconstituted teprotumumab solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. Teprotumumab will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
PlaceboOther
Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Were Proptosis Responders at Week 24Time frame: Week 24
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Macro, Llc
Beverly Hills, California
Cedars-Sinai Medical Center
Los Angeles, California
The Lennar Foundation Medical
Coral Gables, Florida
Bascom Palmer Eye Institute
Miami, Florida
Kellogg Eye Center at University of Michigan
Ann Arbor, Michigan
Casey Eye Institute at Oregon Health and Science University
Portland, Oregon
Hamilton Eye Institute at University of Tennessee Health Science Center
Memphis, Tennessee
Eye Wellness Center
Houston, Texas
Medical College of Wisconsin, The Eye Institute
Milwaukee, Wisconsin
University Hospital Essen, Department of Ophthalmology
Essen, Germany
Johannes Gutenberg University Medical Center
Mainz, Germany
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
University of Pisa, Department of Clinical and Experimental Medicine
Pisa, Italy
University of Pisa,Department of Clinical and Experimental Medicine, Endocrinology Unit
Pisa, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.